Tandem Diabetes Care, Inc.

NasdaqGM TNDM

Tandem Diabetes Care, Inc. Free Cash Flow Yield on January 14, 2025: -1.59%

Tandem Diabetes Care, Inc. Free Cash Flow Yield is -1.59% on January 14, 2025, a 68.17% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.
  • Tandem Diabetes Care, Inc. 52-week high Free Cash Flow Yield is -1.35% on September 30, 2024, which is 14.98% above the current Free Cash Flow Yield.
  • Tandem Diabetes Care, Inc. 52-week low Free Cash Flow Yield is -5.76% on January 30, 2024, which is -262.74% below the current Free Cash Flow Yield.
  • Tandem Diabetes Care, Inc. average Free Cash Flow Yield for the last 52 weeks is -2.73%.
Key data
Date Free Cash Flow Yield Market Value Added (MVA) Price to Book Ratio (P/B) Price to Earnings Ratio (P/E)
Market news
Loading...
NasdaqGM: TNDM

Tandem Diabetes Care, Inc.

CEO Mr. John F. Sheridan
IPO Date Nov. 14, 2013
Location United States
Headquarters 11075 Roselle Street
Employees 2,400
Sector Health Care
Industries
Description

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Similar companies

PODD

Insulet Corporation

USD 267.04

-0.35%

PACB

Pacific Biosciences of California, Inc.

USD 1.85

-7.96%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

SYK

Stryker Corporation

USD 362.80

0.50%

ABT

Abbott Laboratories

USD 113.02

-0.15%

MDT

Medtronic plc

USD 85.25

4.23%

NNOX

Nano-X Imaging Ltd.

USD 7.48

1.22%

PEN

Penumbra, Inc.

USD 252.89

2.41%

BSX

Boston Scientific Corporation

USD 95.65

1.10%

ALGN

Align Technology, Inc.

USD 210.46

-1.51%

StockViz Staff

January 15, 2025

Any question? Send us an email